HomeInsightsStock Comparison

Ajanta Pharma Ltd vs Alivus Life Sciences Ltd Stock Comparison

Ajanta Pharma Ltd vs Alivus Life Sciences Ltd Stock Comparison

Last Updated on: Jun 27, 2025

Key Highlights

  • The Latest Trading Price of Ajanta Pharma Ltd is ₹ 2580 as of 27 Jun 09:32.
  • The P/E Ratio of Ajanta Pharma Ltd changed from 25.6 on March 2020 to 35.7 on March 2025 . This represents a CAGR of 5.70% over 6 yearsThe P/E Ratio of Alivus Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2025 . This represents a CAGR of 0.0% over 6 years.
  • The Market Cap of Ajanta Pharma Ltd changed from ₹ 11921 crore on March 2020 to ₹ 32708 crore on March 2025 . This represents a CAGR of 18.32% over 6 yearsThe Market Cap of Alivus Life Sciences Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 6 years.
  • The revenue of Ajanta Pharma Ltd for the Mar '25 is ₹ 1188 crore as compare to the Dec '24 revenue of ₹ 1176 crore. This represent the growth of 1.02% The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Ajanta Pharma Ltd for the Mar '25 is ₹ 315.26 crore as compare to the Dec '24 ebitda of ₹ 351.27 crore. This represent the decline of -10.25% The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Ajanta Pharma Ltd changed from ₹ 208.12 crore to ₹ 225.26 crore over 8 quarters. This represents a CAGR of 4.04% The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Ajanta Pharma Ltd changed from 25.99 % on March 2020 to 38.28 % on March 2025 . This represents a CAGR of 6.67% over 6 yearsThe Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Ajanta Pharma Ltd

  • Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa.
  • The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets.
  • It produces a comprehensive range of specialty products targeting different therapeutic segments.
  • It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
  • The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia.

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

Ajanta Pharma Ltd News Hub

News

Ajanta Pharma to convene AGM

Ajanta Pharma announced that the 46th Annual General Meeting(AGM) of the company will be h...

Read more

13 Jun 2025 09:37

News

Ajanta Pharma to discuss results

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 April 202...

Read more

22 Apr 2025 17:19

News

Ajanta Pharma Ltd spurts 2.5%, up for five straight sessions

Ajanta Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 2786...

Read more

03 Feb 2025 13:00

News

Ajanta Pharma to conduct board meeting

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 January 2...

Read more

17 Jan 2025 21:11

News

Ajanta Pharma Ltd slips for fifth straight session

Ajanta Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2...

Read more

26 Dec 2024 13:35

News

Ajanta Pharma Ltd soars 1.25%, up for fifth straight session

Ajanta Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 29...

Read more

22 Nov 2024 13:00

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

SWOT Analysis Of Ajanta Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Ajanta Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Ajanta Pharma Ltd and Alivus Life Sciences Ltd

Which company has a larger market capitalization, Ajanta Pharma Ltd or Alivus Life Sciences Ltd?

Market cap of Ajanta Pharma Ltd is 32,064 Cr while Market cap of Alivus Life Sciences Ltd is 12,205 Cr

What are the key factors driving the stock performance of Ajanta Pharma Ltd and Alivus Life Sciences Ltd?

The stock performance of Ajanta Pharma Ltd and Alivus Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ajanta Pharma Ltd and Alivus Life Sciences Ltd?

As of June 27, 2025, the Ajanta Pharma Ltd stock price is INR ₹2567.0. On the other hand, Alivus Life Sciences Ltd stock price is INR ₹995.35.

How do dividend payouts of Ajanta Pharma Ltd and Alivus Life Sciences Ltd compare?

To compare the dividend payouts of Ajanta Pharma Ltd and Alivus Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions